Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review.

Siyuan Gao,Yu Li,Zhichao He,Jianhong Zhu,Dan Liang,Shan Yang,Jiayao Mo,Kakei Lam,Xiaoxia Yu, Ming Huang,Junyan Wu

Expert opinion on drug safety（2023）

引用 0|浏览10

暂无评分

摘要

CDK4/6i had different profiles of thromboembolism. Palbociclib, abemaciclib, or trilaciclib increased the risk of VTE. Ribociclib and abemaciclib showed a weak association with the risk of ATE.

查看译文

关键词

FAERS,arterial thromboembolism,cyclin-dependent kinase 4 and 6 inhibitors,pharmacovigilance,systematic review,venous thromboembolism

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要